Pharmaceutical Preparations Industry - SEC Form 4 Insider Trading Screener
Manufacturing Sector - Chemicals - Pharmaceutical Preparations
100 results - 
- 
- 
- 
- 
- 
- 
- - - - - - | TC | cnt | 1d | 1w | 1m | 6m |
X |
Filing Date |
Trade Date |
Ticker |
Company | Insider Name | Insider Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2020-02-27 | AGRX | Agile Therapeutics Inc | Altomari Alfred | CEO | P - Purchase | $2.71 | +10,000 | 311,611 | +3% | +$27,100 | |||||
| D | 2020-02-27 | LGND | Ligand Pharmaceuticals Inc | Foehr Matthew W | Pres, COO | S - Sale+OE | $110.00 | -7,225 | 155,449 | -4% | -$794,750 | |||||
| M | 2020-02-25 | AKRO | Akero Therapeutics, Inc. | Venbio Global Strategic Fund II L.P. | 10% | S - Sale | $22.80 | -5,904 | 3,227,767 | 0% | -$134,635 | |||||
2020-02-24 | AXGT | Axovant Gene Therapies Ltd. | Roivant Sciences Ltd. | 10% | P - Purchase | $3.75 | +5,333,333 | 18,577,380 | +40% | +$19,999,999 | ||||||
2020-02-25 | AMAG | Amag Pharmaceuticals, Inc. | Armistice Capital, LLC | 10% | P - Purchase | $8.29 | +36,000 | 4,444,000 | +1% | +$298,440 | ||||||
| D | 2020-02-26 | REGN | Regeneron Pharmaceuticals, Inc. | Van Plew Daniel P | EVP, General Mgr Industrial O | S - Sale+OE | $457.23 | -15,642 | 29,788 | -34% | -$7,152,016 | |||||
2020-02-25 | CBIO | Catalyst Biosciences, Inc. | Ling Geoffrey M.D. | Dir | P - Purchase | $6.23 | +3,000 | 3,000 | New | +$18,692 | ||||||
| D | 2020-02-24 | MRUS | Merus N.V. | Throsby Mark | EVP, Chief Scientific Officer | S - Sale+OE | $17.74 | -57,088 | 43,815 | -57% | -$1,012,741 | |||||
| M | 2020-02-24 | TPTX | Turning Point Therapeutics, Inc. | Cui Jingrong Jean | Dir | S - Sale | $52.16 | -21,000 | 2,170,681 | -1% | -$1,095,422 | |||||
2020-02-24 | FULC | Fulcrum Therapeutics, Inc. | Thomson Peter G. | VP Finance, Accounting | S - Sale | $16.83 | -5,000 | 28,571 | -15% | -$84,153 | ||||||
2020-02-25 | ADRO | Aduro Biotech, Inc. | Van Elsas Andrea | Chief Scientific Officer | S - Sale | $3.51 | -6,823 | 438,367 | -2% | -$23,954 | ||||||
2020-02-24 | ADMP | Adamis Pharmaceuticals Corp | Carlo Dennis J Phd | Pres,amp; CEO | S - Sale | $0.60 | -12,436 | 487,326 | -2% | -$7,505 | ||||||
| D | 2020-02-25 | BCEL | Atreca, Inc. | Cavet Guy | Chief Technical Officer | S - Sale+OE | $20.64 | -7,100 | 87,758 | -7% | -$146,538 | |||||
| DM | 2020-02-25 | REGN | Regeneron Pharmaceuticals, Inc. | Landry Robert E | EVP Finance CFO | S - Sale+OE | $452.49 | -414 | 25,145 | -2% | -$187,330 | |||||
2018-11-19 | MDGL | Madrigal Pharmaceuticals, Inc. | Milligan David V | Dir | S - Sale | $131.60 | -10,000 | 20,000 | -33% | -$1,316,000 | ||||||
2020-02-24 | ADMP | Adamis Pharmaceuticals Corp | Marguglio David J. | SVP, Chief Business Officer | S - Sale | $0.60 | -9,948 | 341,243 | -3% | -$6,004 | ||||||
2020-02-24 | ADMP | Adamis Pharmaceuticals Corp | Hopkins Robert O | CFO | S - Sale | $0.60 | -8,420 | 317,480 | -3% | -$5,081 | ||||||
2020-02-24 | ADMP | Adamis Pharmaceuticals Corp | Daniels Karen K. | VP of Operations | S - Sale | $0.60 | -6,229 | 157,460 | -4% | -$3,759 | ||||||
2020-02-24 | ADMP | Adamis Pharmaceuticals Corp | Moss Ronald B. | Chief Medical Officer | S - Sale | $0.06 | -6,229 | 253,195 | -2% | -$396 | ||||||
2018-11-21 | MDGL | Madrigal Pharmaceuticals, Inc. | Milligan David V | Dir | S - Sale | $112.54 | -20,000 | 0 | -100% | -$2,250,800 | ||||||
2020-02-22 | ENDV | Endonovo Therapeutics, Inc. | Collier Alan Brian | Dir | P - Purchase | $0.96 | +100 | 25,819 | 0% | +$96 | ||||||
2020-02-25 | VRTX | Vertex Pharmaceuticals Inc / Ma | Tatsis Ourania | SVP, CRO | S - Sale | $233.17 | -1,296 | 12,738 | -9% | -$302,187 | ||||||
2020-02-25 | VRTX | Vertex Pharmaceuticals Inc / Ma | Silva Paul M | SVP, Controller | S - Sale | $233.45 | -1,080 | 15,101 | -7% | -$252,127 | ||||||
2020-02-25 | VRTX | Vertex Pharmaceuticals Inc / Ma | Sachdev Amit | EVP, Chief Patient Officer | S - Sale | $233.53 | -3,376 | 49,987 | -6% | -$788,402 | ||||||
2020-02-25 | VRTX | Vertex Pharmaceuticals Inc / Ma | Parini Michael | EVP, CL, AO | S - Sale | $233.49 | -3,028 | 26,838 | -10% | -$707,005 | ||||||
2020-02-25 | VRTX | Vertex Pharmaceuticals Inc / Ma | Leiden Jeffrey M | CEO, Pres | S - Sale | $233.46 | -10,550 | 93,021 | -10% | -$2,463,046 | ||||||
2020-02-25 | VRTX | Vertex Pharmaceuticals Inc / Ma | Kewalramani Reshma | EVP, CMO | S - Sale | $233.45 | -3,634 | 26,626 | -12% | -$848,371 | ||||||
2020-02-25 | VRTX | Vertex Pharmaceuticals Inc / Ma | Arbuckle Stuart A | EVP, Chief Commercial Officer | S - Sale | $233.74 | -3,634 | 35,319 | -9% | -$849,418 | ||||||
2020-02-25 | VRTX | Vertex Pharmaceuticals Inc / Ma | Altshuler David | EVP, Global Research, CSO | S - Sale | $233.41 | -3,028 | 28,902 | -9% | -$706,776 | ||||||
| D | 2020-02-25 | ZTS | Zoetis Inc. | Peck Kristin C | CEO | S - Sale+OE | $138.09 | -11,925 | 39,874 | -23% | -$1,646,787 | |||||
| D | 2020-02-25 | AGRX | Agile Therapeutics Inc | Perceptive Advisors LLC | 10% | P - Purchase | $3.00 | +3,000,000 | 14,919,925 | +25% | +$9,000,000 | |||||
| D | 2020-02-25 | ABT | Abbott Laboratories | Moreland Mary K | EVP | S - Sale+OE | $84.93 | -400 | 76,804 | -1% | -$33,972 | |||||
2020-02-24 | ALKS | Alkermes Plc. | Wysenski Nancy | Dir | P - Purchase | $19.65 | +6,940 | 11,242 | +161% | +$136,371 | ||||||
2020-02-25 | ATXI | Avenue Therapeutics, Inc. | Vazzano Joseph Walter | CFO | P - Purchase | $9.09 | +1,200 | 57,863 | +2% | +$10,908 | ||||||
2020-02-25 | ATXI | Avenue Therapeutics, Inc. | Herskowitz Neil | Dir | P - Purchase | $9.31 | +10,000 | 119,663 | +9% | +$93,100 | ||||||
| M | 2020-02-21 | IRWD | Ironwood Pharmaceuticals Inc | Mallon Mark | CEO | S - Sale | $11.63 | -7,984 | 303,425 | -3% | -$92,854 | |||||
2020-02-24 | TYME | Tyme Technologies, Inc. | Demurjian Michael | 10% | S - Sale | $1.30 | -20,000 | 24,030,521 | 0% | -$26,006 | ||||||
2020-02-21 | IRWD | Ironwood Pharmaceuticals Inc | McCourt Thomas A | Pres | S - Sale | $11.63 | -4,177 | 221,062 | -2% | -$48,579 | ||||||
2020-02-21 | IRWD | Ironwood Pharmaceuticals Inc | Macdonald Kelly | Chief Accounting Officer | S - Sale | $11.63 | -3,900 | 83,127 | -4% | -$45,357 | ||||||
2020-02-21 | IRWD | Ironwood Pharmaceuticals Inc | Gilbert Halley E | Chief Admin Officer, SVP | S - Sale | $11.63 | -15,328 | 265,991 | -5% | -$178,265 | ||||||
2020-02-21 | IRWD | Ironwood Pharmaceuticals Inc | Consylman Gina | SVP, CFO, Treasurer | S - Sale | $11.63 | -12,501 | 202,787 | -6% | -$145,387 | ||||||
| D | 2020-02-21 | EBS | Emergent Biosolutions Inc. | Richard Ronald | Dir | S - Sale+OE | $65.00 | -5,152 | 16,395 | -24% | -$334,880 | |||||
| D | 2020-02-25 | VTVT | Vtv Therapeutics Inc. | Perelman Ronald O | 10% | P - Purchase | $1.60 | +1,250,000 | 34,106,212 | +4% | +$2,000,000 | |||||
2020-02-21 | EBS | Emergent Biosolutions Inc. | Hauer Jerome M | Dir | S - Sale | $70.00 | -6,572 | 11,752 | -36% | -$460,040 | ||||||
| D | 2020-02-21 | JNJ | Johnson & Johnson | Mongon Thibaut | EVP, WW Chair, Consumer | S - Sale+OE | $147.96 | -39,224 | 35,815 | -52% | -$5,803,583 | |||||
2020-02-25 | CBIO | Catalyst Biosciences, Inc. | Lawlor Augustine | Dir | S - Sale | $6.10 | -69,401 | 15,608 | -82% | -$423,506 | ||||||
2020-02-21 | CYCN | Cyclerion Therapeutics, Inc. | Huyett William | CFO | S - Sale | $5.12 | -3,559 | 71,417 | -5% | -$18,222 | ||||||
2020-02-24 | REGN | Regeneron Pharmaceuticals, Inc. | Yancopoulos George | Pres, Chief Scientific | S - Sale | $420.17 | -118,123 | 1,081,055 | -10% | -$49,631,741 | ||||||
| D | 2020-02-24 | REGN | Regeneron Pharmaceuticals, Inc. | Brown Michael S | Dir | S - Sale+OE | $419.00 | -2,000 | 16,992 | -11% | -$838,001 | |||||
2020-02-24 | IMGN | Immunogen, Inc. | Ryll Thomas | SVP, Technical Operations | S - Sale | $4.99 | -16,790 | 75,624 | -18% | -$83,782 | ||||||
2020-02-24 | IMGN | Immunogen, Inc. | Enyedy Mark J | CEO | S - Sale | $4.99 | -55,222 | 433,776 | -11% | -$275,558 | ||||||
2020-02-24 | IMGN | Immunogen, Inc. | Berkenblit Anna | SVP, Chief Medical Officer | S - Sale | $4.99 | -25,803 | 98,089 | -21% | -$128,757 | ||||||
2020-02-24 | IMGN | Immunogen, Inc. | Wingrove Theresa | SVP of Regulatory Affairs | S - Sale | $4.99 | -16,147 | 70,498 | -19% | -$80,574 | ||||||
2020-02-24 | IMGN | Immunogen, Inc. | Barrows Craig | EVP, GC | S - Sale | $4.99 | -16,492 | 145,275 | -10% | -$82,295 | ||||||
| DM | 2020-02-20 | EBS | Emergent Biosolutions Inc. | El-Hibri Fuad | COB, 10% | S - Sale+OE | $64.90 | -23,318 | 7,347,423 | 0% | -$1,513,338 | |||||
| AM | 2019-06-07 | CUE | Cue Biopharma, Inc. | Sandercock Colin | SVP, GC, Sec | P - Purchase | $7.90 | +15,125 | 17,125 | +756% | +$119,433 | |||||
| D | 2020-02-20 | URGN | Urogen Pharma Ltd. | Pfreundschuh Peter P. | CFO | S - Sale+OE | $29.68 | -360 | 6,120 | -6% | -$10,685 | |||||
2020-02-24 | INVA | Innoviva, Inc. | Zhen Marianne | Chief Accounting Officer | S - Sale | $14.78 | -2,954 | 21,913 | -12% | -$43,660 | ||||||
| D | 2020-02-21 | ZTS | Zoetis Inc. | Alaix Juan Ramon | Dir | S - Sale+OE | $142.32 | -120,353 | 96,013 | -56% | -$17,128,639 | |||||
2020-02-20 | CALA | Calithera Biosciences, Inc. | Orford Keith | Chief Medical Officer | S - Sale | $8.00 | -3,021 | 8,541 | -26% | -$24,168 | ||||||
| DM | 2020-02-21 | CWBR | Cohbar, Inc. | Biunno Jeffrey Francis | CFO, Treasurer, Secretary | S - Sale+OE | $1.95 | -10,000 | 11,000 | -48% | -$19,500 | |||||
| D | 2020-02-21 | CWBR | Cohbar, Inc. | Cundy Kenneth C | Chief Scientific Officer | S - Sale+OE | $1.90 | -10,000 | 10,000 | -50% | -$19,000 | |||||
2020-02-20 | AGIO | Agios Pharmaceuticals, Inc. | Alenson Carman | Principal Accounting Officer | S - Sale | $53.37 | -2,427 | 184 | -93% | -$129,529 | ||||||
2020-02-21 | VERU | Veru Inc. | Fisch Harry | Dir, 10% | P - Purchase | $4.47 | +1,000 | 8,098,121 | 0% | +$4,470 | ||||||
| D | 2020-02-21 | HZNP | Horizon Therapeutics Public Ltd Co | Walbert Timothy P | COB, Pres, CEO | S - Sale+OE | $35.23 | -93,864 | 856,893 | -10% | -$3,306,829 | |||||
| M | 2020-02-19 | SPPI | Spectrum Pharmaceuticals Inc | McGahan Keith M | GC | S - Sale | $2.81 | -6,008 | 131,992 | -4% | -$16,859 | |||||
| M | 2020-02-19 | SPPI | Spectrum Pharmaceuticals Inc | Riga Thomas J | EVP, COO, CCO | S - Sale | $2.80 | -7,585 | 248,290 | -3% | -$21,216 | |||||
| M | 2020-02-19 | EMMA | Emmaus Life Sciences, Inc. | Niihara Yutaka | COB, CEO, 10% | P - Purchase | $1.80 | +48,000 | 10,564,337 | 0% | +$86,580 | |||||
| M | 2020-02-19 | SPPI | Spectrum Pharmaceuticals Inc | Turgeon Joseph W. | CEO, Pres | S - Sale | $2.80 | -10,012 | 416,806 | -2% | -$28,040 | |||||
| DM | 2020-02-19 | CCXI | Chemocentryx, Inc. | Schall Thomas J. | Pres, CEO | S - Sale+OE | $50.44 | -78,681 | 2,268,557 | -3% | -$3,968,809 | |||||
| D | 2020-02-19 | CCXI | Chemocentryx, Inc. | Kanaya Susan M | EVP, CFO, Sec. | S - Sale+OE | $50.13 | -24,200 | 185,497 | -12% | -$1,213,221 | |||||
| M | 2020-02-19 | SPPI | Spectrum Pharmaceuticals Inc | Gustafson Kurt A | EVP, CFO | S - Sale | $2.80 | -8,066 | 215,892 | -4% | -$22,614 | |||||
| D | 2020-02-19 | CCXI | Chemocentryx, Inc. | Cappel Markus J. | Chief Bus. Officer, Treasurer | S - Sale+OE | $50.36 | -42,631 | 76,247 | -36% | -$2,146,698 | |||||
2020-02-19 | KPTI | Karyopharm Therapeutics Inc. | Shah Jatin | EVP, Chief Medical Officer | S - Sale | $16.48 | -1,375 | 40,759 | -3% | -$22,663 | ||||||
2020-02-19 | KPTI | Karyopharm Therapeutics Inc. | Frenkel Ran | Chief Dev Operations Officer | S - Sale | $16.48 | -2,975 | 36,066 | -8% | -$49,034 | ||||||
2020-02-19 | KPTI | Karyopharm Therapeutics Inc. | Primiano Christopher Brett | EVP, CBO, GC, Secretary | S - Sale | $16.48 | -2,961 | 10,367 | -22% | -$48,803 | ||||||
2020-02-19 | KPTI | Karyopharm Therapeutics Inc. | Shacham Sharon | Pres, CSO | S - Sale | $16.48 | -17,634 | 1,311,611 | -1% | -$290,642 | ||||||
2020-02-19 | UROV | Urovant Sciences Ltd. | Sumitomo Chemical Co., Ltd. | See Footnote (1) | P - Purchase | $13.08 | +103,250 | 22,963,263 | 0% | +$1,350,510 | ||||||
2020-02-19 | KPTI | Karyopharm Therapeutics Inc. | Kauffman Michael | CEO | S - Sale | $16.48 | -17,634 | 1,311,611 | -1% | -$290,642 | ||||||
2020-02-19 | CSTL | Castle Biosciences Inc | Kabakoff David S | Dir, 10% | S - Sale | $32.03 | -25,000 | 1,683,577 | -1% | -$800,750 | ||||||
| DM | 2020-02-19 | KNSA | Kiniksa Pharmaceuticals, Ltd. | Paolini John F. | SVP, Chief Medical Officer | S - Sale+OE | $18.48 | -32,280 | 18,000 | -64% | -$596,487 | |||||
| A | 2020-02-14 | SCPH | Scpharmaceuticals Inc. | Ra Capital Management, L.P. | 10% | P - Purchase | $8.20 | +271,993 | 3,518,998 | +8% | +$2,230,343 | |||||
| D | 2020-02-20 | MGNX | Macrogenics Inc | Risser Eric Blasius | SVP, Chief Business Officer | S - Sale+OE | $10.84 | -500 | 32,468 | -2% | -$5,420 | |||||
| D | 2020-02-20 | CHMA | Chiasma, Inc | Mamluk Roni | Dir | S - Sale+OE | $4.54 | -82,186 | 0 | -100% | -$373,124 | |||||
| DM | 2020-02-19 | ZTS | Zoetis Inc. | Alaix Juan Ramon | Dir | S - Sale+OE | $143.93 | -83,771 | 96,013 | -47% | -$12,056,895 | |||||
| D | 2020-02-20 | ALNY | Alnylam Pharmaceuticals, Inc. | Maraganore John | CEO | S - Sale+OE | $131.85 | -34,765 | 193,126 | -15% | -$4,583,674 | |||||
2020-02-19 | EVFM | Evofem Biosciences, Inc. | Culwell Kelly | Chief Medical Officer | S - Sale | $7.00 | -1,000 | 196,226 | -1% | -$7,000 | ||||||
2020-02-19 | EVFM | Evofem Biosciences, Inc. | Barrans Russell | Chief Commercial Officer | S - Sale | $6.50 | -14,957 | 332,519 | -4% | -$97,221 | ||||||
2020-02-20 | VERU | Veru Inc. | Fisch Harry | Dir, 10% | P - Purchase | $4.51 | +1,000 | 8,097,121 | 0% | +$4,510 | ||||||
2020-02-19 | QURE | Uniqure N.V. | Kapusta Matthew C | CEO, CFO, MD | S - Sale | $64.56 | -7,501 | 284,753 | -3% | -$484,256 | ||||||
2020-02-19 | TEVA | Teva Pharmaceutical Industries Ltd | Drape Eric | EVP Global Operations | S - Sale | $12.51 | -8,000 | 21,494 | -27% | -$100,080 | ||||||
| D | 2020-02-18 | RARX | Ra Pharmaceuticals, Inc. | Farzaneh-Far Ramin | Chief Medical Officer | S - Sale+OE | $46.61 | -10,595 | 7,132 | -60% | -$493,850 | |||||
2020-02-18 | NKTR | Nektar Therapeutics | Zalevsky Jonathan | Chief R, D Officer | S - Sale | $22.35 | -4,774 | 327,073 | -1% | -$106,699 | ||||||
2020-02-18 | NKTR | Nektar Therapeutics | Thomsen Jillian B. | SVP, Chief Accounting Officer | S - Sale | $22.35 | -1,394 | 174,086 | -1% | -$31,156 | ||||||
2020-02-18 | NKTR | Nektar Therapeutics | Robin Howard W | Pres, CEO | S - Sale | $22.35 | -8,448 | 385,281 | -2% | -$188,813 | ||||||
2020-02-18 | NKTR | Nektar Therapeutics | Labrucherie Gil M | SVP, COO, CFO | S - Sale | $22.35 | -5,938 | 253,221 | -2% | -$132,714 | ||||||
2020-02-18 | WVE | Wave Life Sciences Ltd. | Panzara Michael A. | Chief Medical Officer | S - Sale | $7.85 | -2,981 | 39,349 | -7% | -$23,401 | ||||||
| D | 2020-02-18 | GBT | Global Blood Therapeutics, Inc. | Lehrer-Graiwer Joshua | Chief Medical Officer | S - Sale+OE | $69.71 | -1,313 | 2,595 | -34% | -$91,529 | |||||
2020-02-18 | WVE | Wave Life Sciences Ltd. | Bolno Paul | Pres, CEO | S - Sale | $7.85 | -11,451 | 319,758 | -3% | -$89,890 | ||||||
2020-02-18 | WVE | Wave Life Sciences Ltd. | Francis Chris | See Remarks | S - Sale | $7.85 | -2,708 | 31,160 | -8% | -$21,258 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |